Bayer closer to netting Schering AG
Bayer is closer to completing its friendly takeover of Schering AG after Merck KgaA agrees to relinquish its 21.8% share June 14. As of June 13, Bayer reported ownership of 23.36% of Schering shares; Bayer needs a 75% stake to complete the acquisition. Despite dropping its bid in March, Merck had bought Schering stock to bulk up its share (1"The Pink Sheet" March 27, 2006, p. 10). In response, Bayer filed suit in Manhattan federal court June 13, but dropped the complaint after Merck agreed to relinquish its share...
You may also be interested in...
Bayer does not expect to divest any pharmaceutical products following the acquisition of Schering AG, CEO Werner Wenning said March 24 during a briefing outlining the planned merger
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.